AstraZeneca CEO warns Germany on drug access

The CEO of AstraZeneca has cautioned Germany that it risks missing out on new drug launches if it maintains its current pharmaceutical spending plans. He expressed concern that restrictive policies could hinder access to innovative treatments. The Anglo-Swedish drugmaker is urging policymakers to reconsider their approach to ensure patients benefit from the latest medical advancements. This statement highlights potential tensions between pharmaceutical innovation and healthcare budget constraints.